Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Romiplostim (Nplate) peptide icon, one bubble per amino acidRomiplostim (Nplate)14 residuesIEGPTLRQWLAARAEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Romiplostim (Nplate)

ImmuneFDA Approved
~3.5 days half-life·Injection

Also known as: Nplate, AMG 531

A 79% platelet response rate in the important RCT, versus zero on placebo. Romiplostim (Nplate) is a peptibody, an Fc-peptide fusion protein that mimics thrombopoietin and tells the bone marrow to produce more platelets. It earned FDA approval for immune thrombocytopenia (ITP) and carries over five years of long-term safety data. Bone marrow reticulin deposition shows up in roughly 10% of treated patients, though changes reverse after stopping treatment. ITP patients who've exhausted corticosteroids, IVIg, or splenectomy turn to romiplostim for reliable, dose-dependent platelet recovery within one to two weeks.

What Is Romiplostim (Nplate)?

Romiplostim (marketed as Nplate by Amgen) is an Fc-peptide fusion protein that activates the thrombopoietin receptor to drive platelet production. The 2008 Lancet trial (n=125)[1] delivered the headline result: 79% responded versus zero on placebo.

Romiplostim is built from two identical subunits. Each is an Fc-peptide fusion built from two identical subunits. Each subunit pairs a human IgG1 Fc domain with a peptide carrying two thrombopoietin receptor (c-Mpl) binding domains. The result is a molecule that activates the same receptor as endogenous thrombopoietin, triggering megakaryocyte proliferation and platelet production in the bone marrow. Critically, romiplostim shares no amino acid sequence homology with natural TPO. That design choice reduces the risk of cross-reactive antibodies.

In practice, this is a drug for ITP patients who've already tried and failed corticosteroids, IVIg, or splenectomy. FDA approval covers adults and pediatric patients aged one year and older. Dosing starts at 1 mcg/kg subcutaneously once weekly. Clinicians titrate upward in 1 mcg/kg steps, guided by weekly CBC results, until platelets reach at least 50 x 10^9/L. The ceiling is 10 mcg/kg per week.

Long-term data from Kuter and colleagues [2] tracked patients beyond five years and found durable efficacy without new safety signals. About 32% of patients in Phase II data achieved sustained treatment-free remission after dose tapering. The cost, however, is staggering: $5,400 to $11,300 per month without insurance. Amgen's SupportPlus co-pay program and patient assistance options help offset that burden, and roughly 70% of claims show zero out-of-pocket cost.

How Romiplostim (Nplate) Works

Romiplostim binds to and activates the thrombopoietin receptor (c-Mpl) on megakaryocyte precursors in bone marrow. That receptor activation kicks off the JAK2/STAT5 and MAPK signaling cascades downstream.

The practical effect is straightforward. Megakaryocytes proliferate, differentiate, and mature faster. More megakaryocytes means more platelets released into circulation. Platelet count increases are dose-dependent and typically measurable within one to two weeks of starting treatment.

The molecular architecture matters here. Romiplostim is a peptibody: two identical single-chain subunits, each containing a human IgG1 Fc domain fused to a peptide with two c-Mpl binding domains. The Fc portion extends the half-life (median 3.5 days) by engaging neonatal Fc receptors for recycling. The dual binding domains on each subunit increase receptor activation potency.

One feature separates romiplostim from recombinant TPO therapies that were abandoned in the early 2000s. Romiplostim has zero amino acid sequence homology with endogenous thrombopoietin. Earlier recombinant TPO products triggered neutralizing antibodies that cross-reacted with the patient's own TPO, causing paradoxical thrombocytopenia. By using a novel peptide sequence that binds the same receptor through a different structural interface, romiplostim avoids that antibody cross-reactivity problem entirely.

Romiplostim (Nplate) Benefits

  • Romiplostim benefits center on reliable platelet recovery and reduced dependence on immunosuppressive rescue therapies.
  • 79% platelet response rate in the important Lancet 2008 RCT (n=125 ITP patients)[1]. Placebo response was zero.
  • Platelet counts begin rising within one to two weeks of the first injection. That speed matters for patients with active bleeding risk.
  • Five-year follow-up data (Kuter et al.)[2] confirmed durable efficacy without new safety signals emerging over extended treatment.
  • Roughly 32% of Phase II patients achieved sustained treatment-free remission after dose tapering. Some community members in r/ITP report years-long remission after stopping.
  • Enables corticosteroid tapering and IVIg reduction. For patients stuck on chronic prednisone, that alone changes quality of life.
  • Pediatric real-world cohort data from 2024 showed an 83% overall response rate in children aged one year and older, matching the adult profile.

Romiplostim (Nplate): Science vs Community Consensus

Aligned
Scientific Evidence
Strong
Based on 5 key studies·FDA-approved

Romiplostim is an FDA-approved thrombopoietin receptor agonist (TPO-RA) for chronic immune thrombocytopenia (ITP).

Dosing studied: 1–10 mcg/kg SC weekly; titrate in 1 mcg/kg increments based on weekly CBC
Read the evidence (key study, limitations)

The Lancet 2008 RCT (n=125)[1] demonstrated a 79% platelet response rate vs. 0% placebo. Five-year long-term safety data confirmed durable efficacy without new safety signals. Bone marrow reticulin deposition occurs in ~10% of patients; collagen fibrosis in ~2% biopsied (reversible on discontinuation). Rebound thrombocytopenia risk post-discontinuation is well-characterized. No head-to-head RCT vs. eltrombopag. MDS exclusion required: blast progression risk documented.

Key Study

Kuter DJ et al. Lancet 2008 (PMID 18242413): double-blind RCT n=125; 79% platelet response rate vs 0% placebo in ITP patients

Limitations

Bone marrow reticulin deposition in ~10% of patients; collagen fibrosis in ~2% biopsied (reversible on discontinuation). Rebound thrombocytopenia risk post-discontinuation. No head-to-head RCT vs eltrombopag. MDS exclusion required: blast progression risk.

Community Experience
Moderate
3.5/5
Based on ~1,500 r/ITP members

Considered reliable and effective by ITP patients for platelet stabilization.

Community dosing: Strictly follows FDA label: 1 mcg/kg initiation, titrate to platelet target. No off-label dosing patterns observed in r/ITP community.
Read the reports (what users report 4, common issues 5)

High cost and weekly injection burden are the dominant complaints. Rebound thrombocytopenia fear drives reluctance to attempt discontinuation.

What users report (4)
  • Reliable platelet elevation within 1–2 weeks in most responders
  • Reduces or eliminates dependence on steroids and IVIg rescue therapy
  • Some patients achieve sustained treatment-free remission (community estimates ~30% attempt discontinuation)
  • Convenient once-weekly SC vs. frequent IV infusions or daily oral steroids
Common issues (5)
  • Severe headaches and joint/muscle pain 24–48 hours post-injection (most common patient complaint)
  • Extreme cost: $5,400–$11,300/month without insurance coverage
  • Anxiety around rebound thrombocytopenia if dose is missed or discontinuation attempted
  • Weekly injection fatigue during long-term treatment (months to years)
  • Thrombocytosis overshoot risk: platelet counts can spike into dangerous range
Science & Community Aligned

Community use is strictly on-label (ITP treatment under physician supervision). No off-label wellness or performance use observed. Patient-reported outcomes (~80% responders) match published RCT data. Cost and post-injection side effect burden are patient concerns not emphasized in FDA label language.

Romiplostim (Nplate) Dosage Guide

FDA LabelNplate (romiplostim) FDA Prescribing Information (2021)Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner1 mcg/kgWeekly
Moderate3 mcg/kgWeekly
Aggressive10 mcg/kgWeekly
Note:

Romiplostim is weight-based dosing, so the math changes for every patient. Start at 1 mcg/kg weekly. For a 70 kg person, that's 70 mcg.

Reconstitution: add 0.72 mL of sterile water for injection to a 250 mcg vial. That gives you 500 mcg/mL. Swirl gently; don't shake it. Let the vial sit about five minutes until the solution is clear and colorless.

Syringe math for a 70 kg patient on a U-100 insulin syringe at 500 mcg/mL: 70 mcg equals 0.14 mL, which is 14 units. At 3 mcg/kg (210 mcg), you'd pull 42 units. At the max dose of 10 mcg/kg (700 mcg), that's 140 units, so you'd need a 500 mcg vial reconstituted with 1.2 mL sterile water (also yielding 500 mcg/mL).

Don't pool unused portions from multiple vials. The FDA label explicitly prohibits it. Single-use only; discard what's left. Store reconstituted solution at room temperature or refrigerated, but use it within 24 hours.

Cycling

No scheduled off period.

Romiplostim is administered continuously as long-term maintenance therapy, not cycled. Dose is titrated weekly by 1 mcg/kg increments based on platelet counts, starting at 1 mcg/kg. Target platelet count is ≥50 × 10⁹/L. Maximum dose is 10 mcg/kg/week. Do not abruptly discontinue: rebound thrombocytopenia may occur.

Calculate your Romiplostim (Nplate) dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Romiplostim (Nplate) Protocols by Goal

beginnerFDA LabelContinuous long-term therapy; no fixed cycle endpoint. Duration driven by platelet response and remission trials.
Initiation
Wk 1–2
1 mcg/kg · Once weekly · Subcutaneous
Titration
Wk 3–12
Increase by 1 mcg/kg weekly until platelet count ≥50 × 10⁹/L · Once weekly · Subcutaneous
Maintenance
Wk 13+
Lowest effective dose maintaining platelets ≥50 × 10⁹/L · Once weekly · Subcutaneous

Expected: ~80% of ITP patients achieve platelet count ≥50 × 10⁹/L. Platelet response typically begins within 1–2 weeks. Phase II data: ~32% achieve sustained treatment-free remission after dose tapering. Pediatric real-world cohort 2024: 83% overall response rate.

Monitor: CBC with differential weekly during titration → monthly once stable. Peripheral blood smear monthly. Bone marrow biopsy if smear shows new/worsening morphological abnormalities. Weekly CBC for ≥2 weeks post-discontinuation (rebound risk).

How to Inject Romiplostim (Nplate)

  1. 1
    Step 1

    Weigh yourself or confirm your current weight with your prescribing physician. The dose is calculated as mcg per kg of body weight.

  2. 2
    Step 2

    Reconstitute a 250 mcg vial by adding 0.72 mL of sterile water for injection. For a 500 mcg vial, add 1.2 mL. Both yield a concentration of 500 mcg/mL.

  3. 3
    Swirl the vial gently

    Do not shake. Let it sit for about five minutes until the solution turns clear and colorless. If it's cloudy or contains particles, do not use it.

  4. 4
    Calculate your dose

    Example: 70 kg patient at 1 mcg/kg needs 70 mcg. At 500 mcg/mL, that's 0.14 mL, which reads as 14 units on a U-100 insulin syringe.

  5. 5
    Step 5

    Draw the calculated volume using a 27- to 29-gauge insulin syringe. Remove air bubbles by tapping the syringe and pushing gently.

  6. 6
    Inject subcutaneously into the upper arm, thigh, or abdomen

    Rotate injection sites each week.

  7. 7
    Administer once weekly on the same day each week

    Evening dosing can help you sleep through post-injection headache and myalgia.

  8. 8
    Discard any remaining solution in the vial

    Do not save or pool unused portions.

  9. 9
    Step 9

    Store unused vials at 2 to 8 degrees Celsius, protected from light. Do not freeze. Use reconstituted solution within 24 hours.

  10. 10
    Monitor CBC with differential weekly during titration

    Once platelets are stable at 50 x 10^9/L or above for four consecutive weeks, monitoring can extend to monthly.

Mixing your own vial? Use the Romiplostim (Nplate) reconstitution calculator for the exact diluent-to-dose math on any vial size.

Romiplostim (Nplate) Stacking Protocols

Works With

Corticosteroids (prednisone/dexamethasone)

Often continued at reduced dose during romiplostim initiation. Taper as platelets stabilize: this is concurrent standard-of-care ITP therapy, not a peptide stack.

Gradual steroid taper as platelet counts reach and maintain ≥50 × 10⁹/L

Avoid

Eltrombopag (Promacta)

Second TPO receptor agonist: overlapping mechanism risks supranormal platelet counts and dangerous thrombocytosis. FDA label explicitly contraindicates combination. Switch with washout period if changing agents.

Do not combine
Avatrombopag (Doptelet) / Lusutrombopag (Mulpleta)

All TPO receptor agonists share the same mechanism. Combining any two TPO-RAs is contraindicated: uncontrolled platelet overproduction risk.

Do not combine

Estimated Cost

Brand Price
Nplate (Amgen): ~$2,832/vial (250 mcg); ~$5,655/vial (500 mcg). Monthly cost ~$5,400–$11,300+ depending on dose and patient weight. ~70% of Nplate claims have $0 patient out-of-pocket cost (insurance/copay assistance). Amgen SupportPlus co-pay program available for commercially insured. Patient assistance program (free drug) for uninsured/underinsured qualifying patients.

Pricing updated 2026-04-09

Romiplostim (Nplate) Side Effects

Bone marrow reticulin fiber deposition is the safety concern that gets the most attention. Published data show reticulin changes in roughly 10% of treated patients. Collagen fibrosis, the more serious form, appears in about 2% of those biopsied. The reassuring part: these changes have reversed on discontinuation in published cases. The FDA label requires monthly peripheral blood smears to catch early morphological changes (teardrop cells, nucleated red blood cells). If a smear looks abnormal, bone marrow biopsy follows.

Rebound thrombocytopenia after stopping romiplostim is a real risk, not a theoretical one. Platelet counts can drop below the pre-treatment baseline within two weeks of the last dose. The FDA label mandates weekly CBC monitoring for at least two weeks post-discontinuation. ITP patient communities discuss this extensively; the fear of rebound is a primary reason patients hesitate to attempt discontinuation even after months of stable counts.

Thrombocytosis is the opposite problem. Platelet counts can overshoot into a dangerous range above 400 x 10^9/L, raising thromboembolism risk. The protocol is clear: hold the dose for one week, then reduce by 1 mcg/kg. If counts stay raised above 400 on two consecutive readings after dose reduction, discontinue.

For patients with myelodysplastic syndromes (MDS), romiplostim carries a specific warning. Blast progression has been documented. MDS must be excluded before starting treatment, and any non-responding patient at maximum dose should be reassessed for an underlying malignancy rather than assuming dose insufficiency.

Day-to-day side effects are dominated by headache (35% incidence), arthralgia (26%), dizziness (17%), insomnia (16%), and myalgia (14%). Community reports consistently describe headaches and joint or muscle pain peaking 24 to 48 hours after injection. Scheduling the dose for evenings allows sleeping through the worst of it. Abdominal pain (11%), shoulder pain (8%), and paresthesia (6%) round out the common profile.

Neutralizing antibodies to romiplostim or endogenous TPO are rare but monitored. Pregnancy is Category C; use only if the potential benefit justifies fetal risk. Romiplostim should not be used for portal hypertension-related thrombocytopenia, which is not ITP.

Common Issues & Solutions

Platelet count exceeds 400 × 10⁹/L: hold dose for 1 week then reduce by 1 mcg/kg: do not simply continue and monitor; thrombocytosis raises thromboembolism risk.

No platelet response after 4 weeks at 10 mcg/kg: reassess ITP diagnosis before escalating: non-response may indicate MDS, bone marrow failure, or misdiagnosis rather than dose insufficiency.

Post-injection headache and arthralgia (days 1–3 after dose): typically self-limiting; schedule injections for evenings to sleep through the worst of it. OTC analgesics acceptable with physician approval.

Missed a weekly dose: administer as soon as possible within the week; do not double the next dose. Monitor CBC more closely: brief gaps can trigger platelet dip.

IVIg-driven platelet spike: do not adjust romiplostim dose upward based on IVIg-elevated counts: wait 1–2 weeks for IVIg effect to clear before evaluating true romiplostim response.

Ask AI about this page

Ask AI for a second opinion on Romiplostim (Nplate) dosing and side effects

Contraindications

  • Known hypersensitivity to romiplostim or any component of the formulation
  • Myelodysplastic syndromes (MDS) or other hematologic malignancies: risk of blast progression
  • Active thromboembolic disease or high thrombotic risk without anticoagulation
  • Hepatic impairment with portal hypertension-related thrombocytopenia (not ITP)
  • Pregnancy (Category C): use only if potential benefit justifies risk to fetus

Drug Interactions

  • Corticosteroids: romiplostim may allow dose reduction; taper gradually under monitoring
  • Anticoagulants and antiplatelet agents: bleeding risk may change as platelet counts rise; adjust doses accordingly
  • Azathioprine, mycophenolate, other immunosuppressants: additive ITP treatment; monitor closely during tapering
  • IVIg: rescue use may be reduced; do not adjust romiplostim dose based solely on IVIg-induced platelet spikes
  • Eltrombopag (Promacta): do not combine TPO receptor agonists; overlapping mechanism with increased thrombotic risk
  • Second TPO receptor agonist: overlapping mechanism risks supranormal platelet counts and dangerous thrombocytosis. FDA label explicitly contraindicates combination. Switch with washout period if changing agents.
  • All TPO receptor agonists share the same mechanism. Combining any two TPO-RAs is contraindicated: uncontrolled platelet overproduction risk.

Product Quality

Recommended Monitoring

TestWhenTarget
CBC with differentialWeekly during initiation and titration; monthly once platelets stable ≥50 × 10⁹/L for ≥4 consecutive weeksPlatelets 50–200 × 10⁹/L (reduce if >200; hold/reduce if >400)
Peripheral blood smearMonthly throughout treatmentNot listed
Bone marrow biopsyIf peripheral blood smear shows new or worsening morphological abnormalitiesNot listed
Platelet count: post-discontinuation monitoringWeekly for ≥2 weeks after stopping romiplostimNot listed
CBC with differential

Primary efficacy and safety endpoint. Drives all dose adjustments. Detects thrombocytosis (>200 triggers reduction; >400 triggers hold).

Peripheral blood smear

FDA label requirement: detects morphological abnormalities (teardrop cells, nucleated RBCs) signaling possible bone marrow fibrosis or MDS progression.

Bone marrow biopsy

Confirms or excludes reticulin/collagen fiber deposition. Changes are reversible on discontinuation in published cases.

Platelet count: post-discontinuation monitoring

Rebound thrombocytopenia risk. Platelet counts may drop below pre-treatment baseline in the 2 weeks following discontinuation.

Romiplostim (Nplate) Before and After

Week 1

Initiate at 1 mcg/kg weekly; baseline CBC obtained; platelet response not yet expected

Weeks 2-4

Platelet counts begin to rise; dose titrated weekly by 1 mcg/kg based on response

Weeks 4-8

Majority of responders achieve target platelet count ≥50 × 10⁹/L; concurrent ITP medications may begin tapering

Months 3-6

Stable platelet counts maintained; dose adjustments become less frequent; monitoring interval may extend to monthly

Months 6-12+

Durable long-term response; some patients may achieve sustained remission allowing dose reduction

What to Expect

Week 1: The first dose goes in at 1 mcg/kg. Don't expect platelet numbers to budge yet. Most patients report headache and flu-like symptoms 24 to 48 hours after that initial injection. Baseline CBC is your starting reference point.

Weeks 2 to 4: Platelet counts start climbing. Weekly blood draws guide dose increases of 1 mcg/kg at a time. Patients in r/ITP describe real relief when they see counts moving upward for the first time. Post-injection headache and myalgia typically ease up by weeks three and four.

Weeks 4 to 8: Most responders hit the target of 50 x 10^9/L platelets by this point. Bruising decreases. Bleeding anxiety drops. Corticosteroid tapering can begin, and for patients who've been on chronic prednisone, that milestone alone feels transformative.

Months 3 to 6: Stable platelet counts on a steady dose. CBC monitoring can shift from weekly to monthly. Dose reduction trials may start to test whether remission is possible. The weekly injection routine is established; patients describe it as manageable but tiring over months.

Months 6 to 12 and beyond: About 32% of patients in Phase II data achieved sustained treatment-free remission after careful dose tapering. Five-year safety data from Kuter and colleagues [2] confirmed continued efficacy without new safety signals. Reticulin deposition monitoring continues. Patients who attempt discontinuation do so cautiously, with weekly platelet checks and significant anxiety about rebound. Some community members report years-long stable remission after stopping.

Detailed Timeline: Science vs Community

Week 1
Science

First 1 mcg/kg dose administered. No measurable platelet count change expected within the first 7 days.

Community

Most patients feel no platelet benefit at week 1. Headache and flu-like symptoms commonly reported 24–48 hours after first injection.

Weeks 2–4
Science

Measurable platelet count increases. Weekly CBC guides 1 mcg/kg incremental dose adjustments.

Community

Patients describe relief at first rising counts. Anxiety around each weekly lab is common. Post-injection side effects typically diminish in severity by weeks 3–4.

Weeks 4–8
Science

Majority of responders reach platelet count ≥50 × 10⁹/L. Concurrent corticosteroid tapering may begin.

Community

Patients report "life returning to normal": reduced bruising, less bleeding anxiety. Steroid tapering is a major milestone for this group.

Months 3–6
Science

Durable platelet response with stable dose. CBC monitoring can extend to monthly. Dose reduction trials initiated in some patients.

Community

Weekly injection routine is established but reported as a burden. Cost burden and insurance navigation are dominant concerns at this stage.

Months 6–12+
Science

~32% achieve sustained treatment-free remission after dose tapering (Phase II data). 5-year safety data: continued efficacy without new safety signals. Reticulin deposition monitoring ongoing.

Community

Patients who attempt discontinuation do so cautiously with weekly platelet monitoring. Rebound thrombocytopenia is a major fear discussed extensively in r/ITP. Some report years-long stable treatment-free remission.

Pharmacokinetics

Half-Life
84h
Bioavailability
SC: ~65% (estimated from PK modeling)
Tmax
SC: 7-50 hours (median ~14 hours)
Data Confidence
high

Source: Nplate FDA label, section 12.3: in adults with ITP on weekly SC doses of 3 to 15 mcg/kg, half-life ranged from 1 to 34 days (median 3.5 days).

Pharmacokinetics: Active Dose Over Time

t½ = ~3.5 days (median)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
14
Sequence
IEGPTLRQWLAARA
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 267639-76-9

Who Should Consider Romiplostim (Nplate)

  • Adults with chronic immune thrombocytopenia (ITP) with insufficient response to corticosteroids, IVIg, or splenectomy
  • Pediatric patients ≥1 year with ITP lasting ≥6 months with insufficient response to prior treatment
  • ITP patients seeking to reduce corticosteroid dependence
  • Patients with ITP at high bleeding risk due to persistently low platelet counts

Related Peptides

What Changed for Romiplostim (Nplate)

  1. Dosing

    Corrected Oct 9, 2026: romiplostim tiers are 1, 3 and 10 mcg per kg of body weight weekly, not flat mcg doses, per the Nplate label.

    Before: Tiers of 1, 3 and 10 mcg weekly (unit mcg) After: Tiers of 1, 3 and 10 mcg/kg weekly: the label start, the median responder dose (2 to 3 mcg/kg) and the 10 mcg/kg maximum

    Source: Nplate (romiplostim) prescribing information (openFDA label record, SPL version 162, effective Jun 23, 2026) (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Apr 8, 20265 Citations

References

  1. [1]Kuter DJ et al. Efficacy of romiplostim in patients with chronic ITP (Lancet 2008) (opens in a new tab)(n=125)PubMed (opens in a new tab)PubMed
  2. [2]Kuter DJ et al. Long-term treatment with romiplostim: safety and efficacy (Br J Haematol 2013) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Store at 2-8°C (refrigerator) in original carton; protect from light; stable until expiration date
After Reconstitution
Use within 24 hours; store at 25°C or 2-8°C; protect from light; do not pool unused portions
Temperature
2-8°C (36-46°F); do not freeze; do not shake reconstituted solution

Frequently Asked Questions

Yes: counts can exceed 400 x 10^9/L (thrombocytosis), raising clotting risk. That's why the FDA label requires dose reduction or interruption if platelets exceed 400 on two consecutive counts, and discontinuation if they stay above 400 after reducing the dose. Platelet monitoring every 1-2 weeks is mandatory during titration.

Rebound thrombocytopenia is a documented risk: platelets may drop below your pre-treatment baseline, sometimes severely. The FDA label warns to monitor platelets weekly for at least 2 weeks after stopping. Gradual tapering under physician supervision is preferred over abrupt discontinuation.

Reticulin fiber deposition has been observed in trials, including Grade 4 collagen fibrosis in about 2% of biopsied patients. The good news: these changes appear reversible when treatment stops. The FDA label recommends monthly peripheral blood smear evaluation for new or worsening morphological abnormalities, with bone marrow biopsy if anything looks off.

No. Combining two TPO receptor agonists isn't recommended: overlapping mechanism plus the risk of supranormal platelet counts makes it dangerous. Use one at a time, and if switching, allow appropriate washout between them.

The original NEXUS REMS required provider, hospital, and patient enrollment with periodic safety forms. In December 2011, FDA loosened the requirements after post-marketing data showed the safety profile matched the clinical trial data. Healthcare providers no longer need to be registered to prescribe romiplostim.